Post on AMGN Morphs Into Screed About Smart & Dumb Monkeys

I don’t own it, but the NFTRH+ segment in NFTRH 464 noted… “Meanwhile, old friend AMGN is looking interesting these days; somewhat similar to how ABBV looked early this year. If 180 is taken out the target is 210.” …using this chart… Boink… Here is the ABBV chart that it was comp’d to… I am going to stick to my guns for now with a … Continue reading Post on AMGN Morphs Into Screed About Smart & Dumb Monkeys

The Value of Keeping a Well Stocked Bullpen; Amgen You’re In

A bullpen full of quality relievers is critical at a certain point in a ballgame.  That is how I think of my watch list, which includes items I’ve already sold.  Take Amgen for instance; I told myself “don’t be greedy” and sold it at around 172, several weeks ago about 10 bucks above my original target.  I said ‘thank you fine company’ and moved on.  … Continue reading The Value of Keeping a Well Stocked Bullpen; Amgen You’re In

Slow, Steady Profit-Taking Continues (AMGN Edition)

“Don’t be greedy” they teach us in Market Trading 101.  So, more than 10 bucks above the original target I decide to let Amgen go.  Thank you, sir. Subscribe to NFTRH Premium for your 30-45 page weekly report, interim updates and NFTRH+ chart and trade ideas or the free eLetter for an introduction to our work. Or simply keep up to date with plenty of … Continue reading Slow, Steady Profit-Taking Continues (AMGN Edition)

Amgen Trade (Investment?) Working Out Well So Far

Amgen was highlighted in NFTRH and has been updated weekly as part of the NFTRH+, Trading Notes segment.  It seemed like the best of a difficult bunch, where Biotech was concerned and is part of a diversified portfolio of supposed Trump and anti-Trump items (AMGN theoretically being ‘anti’).  I had small losses a couple different times trying to do GILD, which has some issues with … Continue reading Amgen Trade (Investment?) Working Out Well So Far